Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

George S Q Tan

Showing results (1-10 of 12) with videos related to

Pageof 2
Sort By:
British Journal of Clinical Pharmacology|July 24, 2025
Spotlight commentary: Using real-world data for real-world evidence generation to advance drug repurposingGeorge S Q Tan, Jenni Ilomäki
Frontiers in Pharmacology|August 28, 2023
Using administrative healthcare data to evaluate drug repurposing opportunities for cancer: the possibility of using beta-blockers to treat breast cancerGeorge S Q Tan, Edoardo Botteri, Stephen Wood, et al.
Drug Discovery Today|November 7, 2022
Drug repurposing using real-world dataGeorge S Q Tan, Erica K Sloan, Pete Lambert, et al.
Diabetes, Obesity & Metabolism|November 12, 2025
Initiation of sodium-glucose cotransporter-2 inhibitors and the risk of infection-related hospitalisations: A population-based cohort studyMaria J Alfonso Arvez, George S Q Tan, Zanfina Ademi, et al.
Clinical Pharmacology and Therapeutics|July 27, 2025
Risk of Infections with SGLT2 Inhibitors Versus DPP4 Inhibitors: A Population-Based Cohort Study Using Antibiotic Dispensing DataMaria J Alfonso Arvez, George S Q Tan, Sam Wade, et al.
Clinical Pharmacology and Therapeutics|February 9, 2024
SGLT-2 Inhibitor Use and Cause-Specific Hospitalization Rates: An Outcome-Wide Study to Identify Novel Associations of SGLT-2 InhibitorsGeorge S Q Tan, Jedidiah I Morton, Stephen Wood, et al.
Journal of Diabetes Research|October 27, 2025
SGLT2 Inhibitors and the Risk of Infections in Type 2 Diabetes: Systematic Review and Meta-Analyses of Real-World EvidenceMaria J Alfonso Arvez, George S Q Tan, Miriam T Y Leung, et al.
Clinical Pharmacology and Therapeutics|October 6, 2025
Association Discovery Approach in Healthcare Big Data to Identify Drug Safety and Drug Repurposing SignalsGeorge S Q Tan, Lynn Miller, Sam Wade, et al.
American Journal of Epidemiology|September 13, 2024
Tree-based scan statistics to generate drug repurposing hypotheses: a test case using sodium-glucose cotransporter-2 inhibitorsGeorge S Q Tan, Judith C Maro, Shirley V Wang, et al.
Journal of Diabetes|April 10, 2024
The association between sodium glucose cotransporter-2 inhibitors vs dipeptidyl peptidase-4 inhibitors and renal outcomes in people discharged from hospital with type 2 diabetes: A population-based cohort studyKate E D Ziser, Stephen Wood, George S Q Tan, et al.
Pageof 2

Showing results (1-10 of 12) with videos related to

Sort By:
Pageof 2
British Journal of Clinical Pharmacology|July 24, 2025
Spotlight commentary: Using real-world data for real-world evidence generation to advance drug repurposingGeorge S Q Tan, Jenni Ilomäki
Frontiers in Pharmacology|August 28, 2023
Using administrative healthcare data to evaluate drug repurposing opportunities for cancer: the possibility of using beta-blockers to treat breast cancerGeorge S Q Tan, Edoardo Botteri, Stephen Wood, et al.
Drug Discovery Today|November 7, 2022
Drug repurposing using real-world dataGeorge S Q Tan, Erica K Sloan, Pete Lambert, et al.
Diabetes, Obesity & Metabolism|November 12, 2025
Initiation of sodium-glucose cotransporter-2 inhibitors and the risk of infection-related hospitalisations: A population-based cohort studyMaria J Alfonso Arvez, George S Q Tan, Zanfina Ademi, et al.
Clinical Pharmacology and Therapeutics|July 27, 2025
Risk of Infections with SGLT2 Inhibitors Versus DPP4 Inhibitors: A Population-Based Cohort Study Using Antibiotic Dispensing DataMaria J Alfonso Arvez, George S Q Tan, Sam Wade, et al.
Clinical Pharmacology and Therapeutics|February 9, 2024
SGLT-2 Inhibitor Use and Cause-Specific Hospitalization Rates: An Outcome-Wide Study to Identify Novel Associations of SGLT-2 InhibitorsGeorge S Q Tan, Jedidiah I Morton, Stephen Wood, et al.
Journal of Diabetes Research|October 27, 2025
SGLT2 Inhibitors and the Risk of Infections in Type 2 Diabetes: Systematic Review and Meta-Analyses of Real-World EvidenceMaria J Alfonso Arvez, George S Q Tan, Miriam T Y Leung, et al.
Clinical Pharmacology and Therapeutics|October 6, 2025
Association Discovery Approach in Healthcare Big Data to Identify Drug Safety and Drug Repurposing SignalsGeorge S Q Tan, Lynn Miller, Sam Wade, et al.
American Journal of Epidemiology|September 13, 2024
Tree-based scan statistics to generate drug repurposing hypotheses: a test case using sodium-glucose cotransporter-2 inhibitorsGeorge S Q Tan, Judith C Maro, Shirley V Wang, et al.
Journal of Diabetes|April 10, 2024
The association between sodium glucose cotransporter-2 inhibitors vs dipeptidyl peptidase-4 inhibitors and renal outcomes in people discharged from hospital with type 2 diabetes: A population-based cohort studyKate E D Ziser, Stephen Wood, George S Q Tan, et al.
Pageof 2